ZURICH, Oct 16 (Reuters) - Roche Holding AG’s (ROG.VX: Quote, Profile, Research) Mircera anaemia drug is probably on track for U.S. approval with a similar label to that in Europe, the head of its pharmaceuticals business said. “The labelling discussions are underway. The FDA signalled mid-November as an action date and I am thoroughly encouraged. I think we’re on track for a similar label to what we have in Europe,” Roche pharmaceuticals chief executive William Burns said on a conference call.
